Connect Biopharma Announces Completion of Enrollment of Phase 2 Seabreeze STAT Asthma Study Evaluating Rademikibart for the Treatment of Acute Exacerbations in Asthma
– On track to also complete enrollment in the Seabreeze STAT COPD study this month –
– On track to also complete enrollment in the Seabreeze STAT COPD study this month –
Summary aggregated from GlobeNewswire's public RSS feed. The full reporting belongs to GlobeNewswire — please read it on their site.